Cardio Diagnostics Holdings, Inc.

References in this report to Cardio, we, us or the Company refer to Cardio Diagnostics Holdings, Inc. References to our management or our management team refer to the officers and directors of Cardio Diagnostics Holdings, Inc. Our Company Cardio was formed to further develop and commercialize a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease ( CHD ), stroke, heart failure and diabetes, by leveraging our Artificial Intelligence ( AI )-driven Multi-Omics Engine (formerly known as our AI-Integrated Genetic-Epigenetic Engine TM ) . As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases. Cardio aims to become one of the leading medical technology companies for enabling improved prevention, early detection and treatment of cardiovascular disease. Cardio is transforming the approach to cardiovascular disease from reactive to proactive and hope to accelerate the adoption of Precision Medicine for all. We believe that incorporating Cardio’s solutions into routine practice in primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035. Cardio believes that it is the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value propositions for multiple stakeholders including (1) patients, (2) clinicians, (3) hospitals/health systems, (4) employers and (5) payors.